Prostate cancer

Artificial intelligence Steering Testosterone deprivation Treatments in prostate cancer External-beam radiotherapy

Artificial intelligence Steering Testosterone deprivation Treatments in prostate cancer External-beam radiotherapy

Trial overview


Prostate cancer

Eligibility criteria

Inclusion criteria:

  • Adult Male 18 Years and older
  • Participants must have intermediate risk, localised adenocarcinoma of the prostate according to National Comprehensive Cancer Network
  • Estimated life expectancy >10 years
  • Participants must be planned to undergo eligible for curative-intent radiotherapy for prostate cancer

Exclusion Criteria:

  • Participants with insufficient tissue and/or histopathology issues which may arise pertaining to the generation of an accurate ArteraAITM Prostate Test result. Only FFPE specimens can be used for testing, specimens fixed with alternative methods are not eligible.
  • Participants with histological or cytological evidence of neuroendocrine or small cell differentiation.
  • Participants without a histologically proven prostate adenocarcinoma that can be International Society of Urological Pathologists (ISUP) graded
  • Node positive or presence of distant metastases (cN1 or cM1)
  • Participants who have already commenced ADT.
Study details

All participants who choose to enrol in this study will have a sample of their prostate cancer assessed using a new test, ArteraAI, that uses artificial intelligence and a specialised computer algorithm to analyse the characteristics of their specific cancer.

The ArteraAI test will use previously collected tumour samples so that participants will not need to provide further tissue for this study. Depending upon the results of the ArteraAI test, participants may have their cancer treatment plan changed to include or stop use of ADT (testosterone blocking drugs).

A subgroup of participants will also be followed up at five years after they have undergone the ArteraAI test to check their Prostate Specific Antigen (PSA) levels noted in their medical records. PSA is collected as part of normal care follow-up for prostate cancer; therefore, participants won’t need an additional blood test for this. 
It is hoped this research will determine whether use of the ArteraAI test helps doctors to make more informed treatment recommendations for patients with prostate cancer. If the ArteraAI test is found to be useful and the costs associated are not prohibitive to publicly funded medical care, use of the test may be expanded to a greater number of cancer treatment clinics to assist a greater number of patients with prostate cancer.

Further information

Please click here for more information

All GenesisCare Australia sites :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.